PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS
Background and purpose: Currently clinicians wide world are facing with SARS-CoV-2 pandemy, whose clinical features include fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) which can progress to life threatening sequelae. Aim of this study is to evaluate both efficacy and saf...
Saved in:
Main Authors: | Claudio Ucciferri, Barone Mirko, Jacopo Vecchiet, Katia Falasca |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2020-06-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | http://mjhid.org/index.php/mjhid/article/view/4259 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation
by: Claudio Ucciferri, et al.
Published: (2022-02-01) -
Cardiac toxicity associated with HCV direct antiviral agents
by: Claudio Ucciferri, et al.
Published: (2018-10-01) -
SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy
by: Ioana Martac, et al.
Published: (2024-12-01) -
USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
by: Claudio Ucciferri, et al.
Published: (2010-02-01) -
USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
by: Paola Mancino, et al.
Published: (2010-03-01)